Anti-infective antibodies are being developed by Regeneron Pharmaceuticals, in collaboration with the Biomedical Advanced Research and Development Authority (BARDA), i for the treatment of infectious diseases, including influenza virus infections, COVID-2019 infections and multiple other emerging pathogens that pose significant risk to public health. Regeneron is using its proprietary VelociSuite® and VelocImmune technologies to facilitate rapid identification, preclinical validation and development of suitable antibody candidates. Early research is ongoing in the US.
In February 2020, Regeneron Pharmaceuticals expanded its agreement with the U.S. Department of Health and Human Services (HHS) to develop new treatments combating the COVID-2019 infections. Previously, in October 2017, Regeneron Pharmaceuticals entered into a research and development agreement with the Biomedical Advanced Research and Development Authority (BARDA) of the US Department of Health and Human Services (HHS), for the discovery, research, development and manufacturing of a portfolio of antibodies for the treatment of infectious diseases, including influenza virus and multiple other emerging pathogens. The emerging pathogens treatment portfolio will be developed using an Other Transaction Agreement (OTA) with a term of 10 years, to provide a funding and collaboration vehicle for HHS. Under the terms of the agreement, HHS will fund 80 percent of costs for research, development and manufacturing activities for selected antibodies to Regeneron. BARDA and Regeneron will jointly select up to ten target pathogens. The first selected program will target influenza virus and receive initial funding of more than $US18 million for early-stage antibody discovery, development and manufacturing of the drug.